Nasdaq Analyst Becomes Optimistic; Check Out the Top 5 Upgrades for Thursday
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 20 2025
0mins
Should l Buy BRKR?
Source: Benzinga
Analyst Upgrades: Several Wall Street analysts have upgraded their ratings on various companies, including AVITA Medical, Agios Pharmaceuticals, Nasdaq, Marsh & McLennan, and Parsons Corp.
AVITA Medical: BTIG analyst Ryan Zimmerman upgraded AVITA Medical from Sell to Neutral, with shares closing at $3.95.
Agios Pharmaceuticals: Leerink Partners analyst Andrew Berens upgraded Agios Pharmaceuticals from Market Perform to Outperform, lowering the price target from $40 to $34, with shares closing at $22.34.
Nasdaq and Marsh & McLennan: Morgan Stanley upgraded Nasdaq from Equal-Weight to Overweight, raising the price target from $97 to $110, while Barclays upgraded Marsh & McLennan from Equal-Weight to Overweight, lowering the price target from $221 to $206.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BRKR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BRKR
Wall Street analysts forecast BRKR stock price to rise
12 Analyst Rating
7 Buy
4 Hold
1 Sell
Moderate Buy
Current: 36.740
Low
40.00
Averages
52.18
High
60.00
Current: 36.740
Low
40.00
Averages
52.18
High
60.00
About BRKR
Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic solutions. The Company's segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). Its BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research and development solutions in chemical research fields. Its BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bruker Accelerates Semiconductor Materials Characterization Technology
- Technology Upgrade: Bruker Corporation has announced the accelerated development of its photothermal AFM-IR spectroscopy capabilities to address research challenges in the semiconductor industry, which is expected to enhance its market position in semiconductor materials characterization.
- Collaborative Project: In a joint development project with imec, a world-leading semiconductor technology research hub, Bruker has installed its Dimension IconIR system to evaluate the application of photothermal AFM-IR in addressing critical research questions, thereby advancing semiconductor process development.
- Nanoscale Analysis Capability: The IconIR system enables label-free chemical analysis with sub-5-nanometer resolution, facilitating a deeper understanding of EUV photoresist chemistry and material interactions, which is anticipated to provide crucial chemical insights for next-generation device concepts.
- Market Outlook: Bruker's Dimension IconIR system combines nanoscale infrared spectroscopy with scanning probe microscopy, offering monolayer sensitivity and high-resolution chemical imaging, which is expected to drive precise characterization of semiconductor materials and structures, further solidifying its leadership in the high-performance scientific instruments market.
See More
PTAB Revokes Central Claims of U.S. Patent 11,435,360
- Patent Claims Revoked: The U.S. Patent Trial and Appeal Board (PTAB) has revoked the sole independent claim and other central claims of U.S. Patent No. 11,435,360, significantly impacting the detection technology for biomolecule coronas.
- Scientific Literature Validation: Dr. Oliver Rinner, co-founder of Biognosys AG, stated that this outcome confirms their belief that the fundamental concepts were already known in scientific literature, raising questions about the patent's validity.
- Commitment to Innovation: PreOmics and Biognosys are dedicated to advancing high-performance sample preparation and software for proteomics and multiomics workflows, ensuring ongoing innovation to meet global researchers' needs.
- Collaborative Industry Strategy: The Biognosys Group integrates industry-leading consumables, software, and instruments while maintaining a vendor-neutral strategy, ensuring broad compatibility of solutions across major mass spectrometry platforms to foster open collaboration in the scientific community.
See More
Bruker Corp Shares Enter Oversold Territory
- Oversold Signal: Bruker Corp (Ticker: BRKR) entered oversold territory on Friday with an RSI reading of 29.5, hitting a low of $36.515 per share, indicating that recent heavy selling may be exhausting, thus presenting potential buying opportunities for investors.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 41.2, BRKR's 29.5 RSI suggests relative weakness, which may attract investors looking for rebounds, especially amid increasing market volatility.
- Historical Performance Analysis: BRKR's 52-week low is $28.53 and high is $56.22, with the last trade at $36.68, reflecting significant price fluctuations over the past year, prompting investors to monitor future price movements closely.
- Investor Strategy: Given BRKR's oversold condition, investors may seek suitable entry points, particularly if market sentiment shifts positively, potentially providing support for future stock price rebounds.
See More
Bruker Unveils New Spatial Biology Platforms at AGBT 2026
- Portfolio Innovations: Bruker Corporation announced significant advancements at the 2026 AGBT meeting, including the launch of the CellScape XR spatial proteomics platform and the unique CosMx mouse whole transcriptome panel, reinforcing its leadership in spatial biology and accelerating scientific discovery and translational research.
- PaintScape Pre-Orders: The company is now accepting pre-orders for the PaintScape system, the first high-precision platform enabling multiplexed, direct visualization of the 3D genome in single cells, with shipments expected to begin this spring, allowing researchers to explore the relationship between genome structure and disease biology.
- CellScape XR Performance Enhancements: The next-generation CellScape XR platform integrates major advancements in instrumentation, software, and assay ecosystems, significantly improving data quality and throughput, which is expected to enhance clinical applications and help customers achieve greater impact in their scientific endeavors.
- GeoMx DSP Multiomics Platform: Bruker's GeoMx Digital Spatial Profiler enables large-scale spatial biomarker discovery with over 1,200 protein targets, showcasing its extensive application potential in oncology and neuroscience, further advancing research in spatial biology.
See More
The Dollar's Dominance Is Winding Down: Strategies for Investors.
- Dollar Decline: The dollar is experiencing a decline, impacting investors' strategies and expectations.
- Investor Adaptation: Investors need to adjust to the changing economic landscape and find ways to navigate the challenges posed by a weaker dollar.
See More
Bruker Corp Reports Mixed Q4 Financial Results
- Earnings Performance: Bruker reported Q4 earnings of $0.59 per share, missing the analyst consensus of $0.65, indicating pressure on profitability that may affect investor confidence.
- Sales Beat Expectations: The company achieved quarterly sales of $977.2 million, surpassing the analyst estimate of $960.834 million, suggesting strong market demand that could bolster future performance expectations.
- Future Outlook: Bruker projects FY2026 adjusted EPS between $2.10 and $2.15, slightly below the market estimate of $2.13, reflecting a cautious stance on future profit growth.
- Analyst Rating Adjustments: Barclays analyst maintained an Overweight rating on Bruker but lowered the price target from $55 to $50, indicating a cautious outlook on the company's future performance.
See More
Bruker Accelerates Semiconductor Materials Characterization Technology
- Technology Upgrade: Bruker Corporation has announced the accelerated development of its photothermal AFM-IR spectroscopy capabilities to address research challenges in the semiconductor industry, which is expected to enhance its market position in semiconductor materials characterization.
- Collaborative Project: In a joint development project with imec, a world-leading semiconductor technology research hub, Bruker has installed its Dimension IconIR system to evaluate the application of photothermal AFM-IR in addressing critical research questions, thereby advancing semiconductor process development.
- Nanoscale Analysis Capability: The IconIR system enables label-free chemical analysis with sub-5-nanometer resolution, facilitating a deeper understanding of EUV photoresist chemistry and material interactions, which is anticipated to provide crucial chemical insights for next-generation device concepts.
- Market Outlook: Bruker's Dimension IconIR system combines nanoscale infrared spectroscopy with scanning probe microscopy, offering monolayer sensitivity and high-resolution chemical imaging, which is expected to drive precise characterization of semiconductor materials and structures, further solidifying its leadership in the high-performance scientific instruments market.
See More
PTAB Revokes Central Claims of U.S. Patent 11,435,360
- Patent Claims Revoked: The U.S. Patent Trial and Appeal Board (PTAB) has revoked the sole independent claim and other central claims of U.S. Patent No. 11,435,360, significantly impacting the detection technology for biomolecule coronas.
- Scientific Literature Validation: Dr. Oliver Rinner, co-founder of Biognosys AG, stated that this outcome confirms their belief that the fundamental concepts were already known in scientific literature, raising questions about the patent's validity.
- Commitment to Innovation: PreOmics and Biognosys are dedicated to advancing high-performance sample preparation and software for proteomics and multiomics workflows, ensuring ongoing innovation to meet global researchers' needs.
- Collaborative Industry Strategy: The Biognosys Group integrates industry-leading consumables, software, and instruments while maintaining a vendor-neutral strategy, ensuring broad compatibility of solutions across major mass spectrometry platforms to foster open collaboration in the scientific community.
See More
Bruker Corp Shares Enter Oversold Territory
- Oversold Signal: Bruker Corp (Ticker: BRKR) entered oversold territory on Friday with an RSI reading of 29.5, hitting a low of $36.515 per share, indicating that recent heavy selling may be exhausting, thus presenting potential buying opportunities for investors.
- Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 41.2, BRKR's 29.5 RSI suggests relative weakness, which may attract investors looking for rebounds, especially amid increasing market volatility.
- Historical Performance Analysis: BRKR's 52-week low is $28.53 and high is $56.22, with the last trade at $36.68, reflecting significant price fluctuations over the past year, prompting investors to monitor future price movements closely.
- Investor Strategy: Given BRKR's oversold condition, investors may seek suitable entry points, particularly if market sentiment shifts positively, potentially providing support for future stock price rebounds.
See More
Bruker Unveils New Spatial Biology Platforms at AGBT 2026
- Portfolio Innovations: Bruker Corporation announced significant advancements at the 2026 AGBT meeting, including the launch of the CellScape XR spatial proteomics platform and the unique CosMx mouse whole transcriptome panel, reinforcing its leadership in spatial biology and accelerating scientific discovery and translational research.
- PaintScape Pre-Orders: The company is now accepting pre-orders for the PaintScape system, the first high-precision platform enabling multiplexed, direct visualization of the 3D genome in single cells, with shipments expected to begin this spring, allowing researchers to explore the relationship between genome structure and disease biology.
- CellScape XR Performance Enhancements: The next-generation CellScape XR platform integrates major advancements in instrumentation, software, and assay ecosystems, significantly improving data quality and throughput, which is expected to enhance clinical applications and help customers achieve greater impact in their scientific endeavors.
- GeoMx DSP Multiomics Platform: Bruker's GeoMx Digital Spatial Profiler enables large-scale spatial biomarker discovery with over 1,200 protein targets, showcasing its extensive application potential in oncology and neuroscience, further advancing research in spatial biology.
See More
The Dollar's Dominance Is Winding Down: Strategies for Investors.
- Dollar Decline: The dollar is experiencing a decline, impacting investors' strategies and expectations.
- Investor Adaptation: Investors need to adjust to the changing economic landscape and find ways to navigate the challenges posed by a weaker dollar.
See More
Bruker Corp Reports Mixed Q4 Financial Results
- Earnings Performance: Bruker reported Q4 earnings of $0.59 per share, missing the analyst consensus of $0.65, indicating pressure on profitability that may affect investor confidence.
- Sales Beat Expectations: The company achieved quarterly sales of $977.2 million, surpassing the analyst estimate of $960.834 million, suggesting strong market demand that could bolster future performance expectations.
- Future Outlook: Bruker projects FY2026 adjusted EPS between $2.10 and $2.15, slightly below the market estimate of $2.13, reflecting a cautious stance on future profit growth.
- Analyst Rating Adjustments: Barclays analyst maintained an Overweight rating on Bruker but lowered the price target from $55 to $50, indicating a cautious outlook on the company's future performance.
See More
